Annotation Detail

Information
Associated Genes
NPM1
Associated Variants
NPM1 EXON 12 MUTATION
NPM1 EXON 12 MUTATION
Associated Disease
acute myeloid leukemia
Source Database
CIViC Evidence
Description
Complete remission rates were higher (P<0.001) and both disease-free survival (N=205 vs 352, P=0.041) and overall survival (N=372 vs 956, P=0.022) were longer for AML patients with Exon 12 NPM1 mutations (irrespective of FLT3 status) than those with wildtype NPM1. Improved CR rates were also higher for those with NPM1 exon 12 mutations and normal karyotype. In multivariate analysis, NPM1 mutation alone (FLT3 wildtype) was associated with improved overall survival (but not DFS) in the entire cohort and in normal karyotype patients <60 years old.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/175
Gene URL
https://civic.genome.wustl.edu/links/genes/35
Variant URL
https://civic.genome.wustl.edu/links/variants/86
Rating
3
Evidence Type
Prognostic
Disease
Acute Myeloid Leukemia
Evidence Direction
Supports
Evidence Level
B
Clinical Significance
Better Outcome
Pubmed
16455956
Drugs